Journal article
Re-Endothelialization of Decellularized Liver Scaffolds: A Step for Bioengineered Liver Transplantation
Frontiers in bioengineering and biotechnology, Vol.10, pp.833163-833163
03/10/2022
DOI: 10.3389/fbioe.2022.833163
PMCID: PMC8960611
PMID: 35360393
Abstract
Bioengineered livers (BELs) are an attractive therapeutic alternative to address the donor organ shortage for liver transplantation. The goal of BELs technology aims at replacement or regeneration of the native human liver. A variety of approaches have been proposed for tissue engineering of transplantable livers; the current review will highlight the decellularization-recellularization approach to BELs. For example, vascular patency and appropriate cell distribution and expansion are critical components in the production of successful BELs. Proper solutions to these components of BELs have challenged its development. Several strategies, such as heparin immobilization, heparin-gelatin, REDV peptide, and anti-CD31 aptamer have been developed to extend the vascular patency of revascularized bioengineered livers (rBELs). Other novel methods have been developed to enhance cell seeding of parenchymal cells and to increase graft functionality during both bench and
in vivo
perfusion. These enhanced methods have been associated with up to 15 days of survival in large animal (porcine) models of heterotopic transplantation but have not yet permitted extended survival after implantation of BELs in the orthotopic position. This review will highlight both the remaining challenges and the potential for clinical application of functional bioengineered grafts.
Details
- Title: Subtitle
- Re-Endothelialization of Decellularized Liver Scaffolds: A Step for Bioengineered Liver Transplantation
- Creators
- Kewei Li - Sichuan UniversityMohammad Tharwat - Mayo Clinic in ArizonaEllen L. Larson - Mayo Clinic in ArizonaPhilipp Felgendreff - Mayo Clinic in ArizonaSeyed M. Hosseiniasl - Mayo Clinic in ArizonaAnan Abu Rmilah - Mayo ClinicKhaled Safwat - Zagazig UniversityJeffrey J. Ross - Miromatrix MedicalScott L. Nyberg - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Frontiers in bioengineering and biotechnology, Vol.10, pp.833163-833163
- DOI
- 10.3389/fbioe.2022.833163
- PMID
- 35360393
- PMCID
- PMC8960611
- NLM abbreviation
- Front Bioeng Biotechnol
- ISSN
- 2296-4185
- eISSN
- 2296-4185
- Publisher
- Frontiers Media S.A
- Grant note
- ;
- Alternative title
- Li et al
- Language
- English
- Date published
- 03/10/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984845397302771
Metrics
1 Record Views